Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis

(marketscreener.com) CNM-Au8 met primary and secondary endpoints of Low Contrast Letter Acuity and modified Multiple Sclerosis Functional Composite compared to placebo over 48 weeks in the mITT populationConsistent improvements favoring CNM-Au8 were seen across paraclinical biomarkers, providing physiological evidence for its potential neuroprotective and...https://www.marketscreener.com/quote/stock/CLENE-INC-45490772/news/Clene-Reports-Positive-Topline-Results-for-CNM-Au8-in-the-Phase-2-VISIONARY-MS-Trial-in-Multiple-Sc-41316823/?utm_medium=RSS&utm_content=20220815